Open access · CC-BY
via OpenAlex
Bioenergetic and Proteomic Profiling of Immune Cells in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients: An Exploratory Study
Paula Fernández‐Guerra, Ana Carlota Gonzalez-Ebsen, Susanne E. Boonen, Julie Courraud, Niels Gregersen, Jesper Mehlsen, Johan Palmfeldt, Rikke Katrine Jentoft Olsen, Louise Brinth
Biomolecules · 2021 · ▲ 36 citations
Abstract
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a heterogeneous, debilitating, and complex disease. Along with disabling fatigue, ME/CFS presents an array of other core symptoms, including autonomic nervous system (ANS) dysfunction, sustained inflammation, altered energy metabolism, and mitochondrial dysfunction(definition). Here, we evaluated patients' symptomatology and the mitochondrial metabolic parameters in peripheral blood mononuclear cells (PBMCs) and plasma from a clinically well-characterised cohort of six ME/CFS patients compared to age- and gender-matched controls. We performed a comprehensive cellular assessment using bioenergetics (extracellular flux analysis) and protein profiles (quantitative mass spectrometry-based proteomics) together with self-reported symptom measures of fatigue, ANS dysfunction, and overall physical and mental well-being. This ME/CFS cohort presented with severe fatigue, which correlated with the severity of ANS dysfunction and overall physical well-being. PBMCs from ME/CFS patients showed significantly lower mitochondrial coupling efficiency. They exhibited proteome alterations, including altered mitochondrial metabolism, centred on pyruvate dehydrogenase and coenzyme A metabolism, leading to a decreased capacity to provide adequate intracellular ATP levels. Overall, these results indicate that PBMCs from ME/CFS patients have a decreased ability to fulfill their cellular energy demands.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/biom11070961
- Canonical
- link ↗
- Fetched
- 2026-06-06 MST
Cite this
APA
Fernández‐Guerra, P., Gonzalez-Ebsen, A.C., Boonen, S.E., Courraud, J., Gregersen, N., Mehlsen, J., Palmfeldt, J., Olsen, R.K.J., & Brinth, L. (2021). Bioenergetic and Proteomic Profiling of Immune Cells in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients: An Exploratory Study. <em>Biomolecules</em>. https://doi.org/10.3390/biom11070961
Vancouver
Fernández‐Guerra P, Gonzalez-Ebsen AC, Boonen SE, Courraud J, Gregersen N, Mehlsen J, et al. Bioenergetic and Proteomic Profiling of Immune Cells in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients: An Exploratory Study. Biomolecules. 2021. doi:10.3390/biom11070961.
BibTeX
@article{paula2021Bioene,
title = {Bioenergetic and Proteomic Profiling of Immune Cells in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients: An Exploratory Study},
author = {Paula Fernández‐Guerra and Ana Carlota Gonzalez-Ebsen and Susanne E. Boonen and Julie Courraud and Niels Gregersen and Jesper Mehlsen and Johan Palmfeldt and Rikke Katrine Jentoft Olsen and Louise Brinth},
journal = {Biomolecules},
year = {2021},
doi = {10.3390/biom11070961},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Laboratory Investigation 2013
Open access · CC-BY
Methods for defining distinct bioenergetic profiles in platelets, lymphocytes, monocytes, and neutrophils, and the oxidative burst from human blood
Signal Transduction and Targeted Therapy 2023
Open access · CC-BY
Inflammation and aging: signaling pathways and intervention therapies
Microbiome 2016
Open access · CC-BY
Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome
Frontiers in Cell and Developmental Biology 2015
Open access · CC-BY
Mitochondrial dysfunction in inflammatory bowel disease
Allergy 2023
Open access · CC-BY
Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology
GeroScience 2023
Open access · CC-BY